ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Feb 01, 2022 17:43 JST
Source:
Eisai
Eisai Receives the Tokyo Governor Prize for Corporate Governance of the Year 2021
TOKYO, Feb 01, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that it was selected as the winner of the Tokyo Governor Prize for Corporate Governance of the Year 2021, which is an award program organized by the Japan Association of Corporate Directors (JACD). The award ceremony was held on January 31, 2022.
Left: Mr. Eiichiro Kodama: Director General for Global Financial City Strategy, Office of the Governor for Policy Planning, Tokyo Metropolitan Government, Right: Haruo Naito: CEO, "Eisai"
The awards have been established to recognize the companies which have achieved and maintained the medium to long term profitability by implementing good corporate governance, since 2015. Among the eligible companies for selection of the Corporate Governance of the Year 2021, the Tokyo Governor Prize goes to a company which has excellent corporate governance and also practices ESG activities such as environmental activities, women empowerment, initiatives for diversity and work style reforms.
Commenting on the reason for selecting Eisai, Mr. Eiichiro Kodama, Director General for Global Financial City Strategy, Office of the Governor for Policy Planning, Tokyo Metropolitan Government stated, "Eisai is a pioneer in incorporating its corporate philosophy into the Articles of Incorporation and practicing "Purpose Management." With regard to corporate governance, Eisai makes the most of its status as a company with a nomination committee, etc., system to clearly separate management oversight and business execution, and places great importance to dialogue with its stakeholders including patients. In terms of ESG, Eisai is a signatory to the United Nations Global Compact and actively participates in climate change-related initiatives such as "RE100" and the Japan Climate Initiative. In addition, Eisai is taking on the challenge of quantifying values that do not appear on the balance sheet, such as investments in human capital, with attempting to select KPIs related ESG including the ratio of women in management positions, analyze its relationship with PBR (Price Book-value Ratio), and utilize the verification results for engagement with investors. Eisai is actively working to tell the story of the cause-and-effect relationship between the ESG initiatives and the enhancement of corporate value, thus taking on the extremely important challenge to visualize invisible value, embody the value of ESG, and disseminate them."
Eisai defines its corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides" in the Articles of Incorporation, and shares it with its stakeholders. Eisai calls this philosophy the human health care (hhc) philosophy, in one word, and believes that practicing philosophical management based on the hhc philosophy will contribute to achieving Sustainable Development Goals (SDGs) and further enhance its corporate value.
Eisai is committed to further strengthening its corporate governance in order to realize the hhc philosophy.
For further information on the awards, please visit www.jacd.jp/en/conference.
*Corporate Governance of the Year is a registered trademark of JACD
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech
Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Mitsubishi Motors to Deliver Multi-Terrain Performance and Refined Ride Comfort with its All-New Pajero Cross-Country SUV
Aug 04, 2026 21:59 JST
MHI and Green AI Co., Ltd. Commence Partnership to Improve Energy Efficiency in Industries
Aug 04, 2026 21:19 JST
TANAKA Develops MOC1-30 Series Methane Oxidation Catalyst with High Sulfur Resistance and More Than 80% Methane Conversion
Aug 04, 2026 21:00 JST
Fujitsu, Monash and CSIRO strengthen Australia-Japan quantum partnership
Aug 04, 2026 11:29 JST
ispace and Mitsubishi Heavy Industries Agree to Launch Mission 3 ULTRA Lunar Lander Aboard H3 Rocket
Jul 29, 2026 21:08 JST
Mazda Begins Local Assembly of MAZDA CX-30 in Indonesia
Jul 29, 2026 20:53 JST
Fujitsu initiates development of proprietary AI platform for financial institutions
Jul 28, 2026 19:53 JST
Toyota, Volvo Group and Daimler Truck AG sign binding agreement for Toyota to join cellcentric as equal shareholder
Jul 28, 2026 00:39 JST
Pfizer and Eisai Commence Co-promotion of "NURTEC(R)" for the Acute Treatment and Prophylaxis (Preventive Treatment) of Migraine
Jul 27, 2026 23:50 JST
Launch of a proof-of-concept experiment for a next-generation distributed AI processing infrastructure aiming to realize the Watt-Bit vision
Jul 27, 2026 23:24 JST
Next-generation spectator experience at KYOJO CUP: AI selects and delivers "The moment you want to see" with ultra-low latency
Jul 27, 2026 22:40 JST
Sharp Acquires Vietnamese Corporation Engaged in Solar EPC And O&M Business as A Wholly Owned Subsidiary
Jul 27, 2026 22:02 JST
Collaboration Agreement announced by Sovereign Effects Partners to support GCAP
Jul 27, 2026 21:49 JST
Chunghwa Telecom, Fujitsu and 1Finity to accelerate All-Photonics Network deployment and advance quantum technologies in Taiwan through strategic partnership
Jul 27, 2026 21:08 JST
JCB and Fiuu Collaborate to Expand JCB Acceptance Across Southeast Asia
Jul 23, 2026 12:00 JST
Marketing Authorization Application for In-house Developed Insomnia Drug Lemborexant Accepted for Evaluation by European Medicines Agency (EMA)
Jul 18, 2026 00:24 JST
Hitachi and NVIDIA collaborate to advance HMAX and enable end-to-end autonomous operations through the integrated control of physical AI
Jul 17, 2026 23:35 JST
Toyota's First "BE creation" Spin-Off Begins Operations in Japan
Jul 17, 2026 23:00 JST
MHI Advances AI Infrastructure Commercialization with U.S. Deployment of 10MW-Class Chiller and MCP Development
Jul 17, 2026 22:47 JST
Noetra Launches Full-Scale R&D for Japan-Developed Multimodal Foundation Model
Jul 17, 2026 22:16 JST
More Latest Release >>
Related Release
Pfizer and Eisai Commence Co-promotion of "NURTEC(R)" for the Acute Treatment and Prophylaxis (Preventive Treatment) of Migraine
7/27/2026 11:50:00 PM JST
Marketing Authorization Application for In-house Developed Insomnia Drug Lemborexant Accepted for Evaluation by European Medicines Agency (EMA)
7/18/2026 12:24:00 AM JST
LEQEMBI(R) Real-World LEADER Study Presented at AAIC(R) 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
7/16/2026 12:18:00 AM JST
FDA Approves LEQEMBI IQLIK(R) (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
7/15/2026 11:51:00 PM JST
Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer's Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer's Association International Conference(R) (AAIC(R)) 2026
7/15/2026 11:21:00 PM JST
LEQEMBI(R) Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference(R) (AAIC(R)) 2026
7/14/2026 12:06:00 AM JST
Eisai to Showcase Alzheimer's Disease Portfolio with More Than 50 Presentations at the Alzheimer's Association International Conference(R) 2026 (AAIC(R))
7/2/2026 10:45:00 PM JST
UCL and Eisai renew partnership to accelerate treatments for neurodegenerative diseases
7/2/2026 10:01:00 PM JST
Eisai Announces Strategic Investment Supported by the UK Government's LSIMF
6/17/2026 1:28:00 PM JST
Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026
5/22/2026 12:23:00 AM JST
More Press release >>